A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines Against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)

Overview

Journal Vaccines (Basel)

Date 2023 Feb 28

PMID 36851102

Authors

Hassen Mohammed

Dan Duy Pham-Tran

Zi Yi Michelle Yeoh

Bing Wang

Mark McMillan

Prabha H Andraweera

Helen S Marshall

Affiliations

Soon will be listed here.

Abstract

Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, and severe outcomes. We systematically searched literature up to 1 August 2022. Meta-analysis was performed with the DerSimonian-Laird random-effects model to estimate the pooled vaccine effectiveness (VE). Overall, 28 studies were included representing 11 million individuals. The pooled VE against Omicron infection was 20.4% (95%CI: 12.1-28.7%) and 23.4% (95%CI: 13.5-33.3%) against symptomatic infection with variation based on vaccine type and age groups. VE sharply declined from 28.1% (95%CI: 19.1-37.1%) at three months to 3.9% (95%CI: -24.8-32.7%) at six months. Similar trends were observed for symptomatic Omicron infection. A booster dose restored protection against Omicron infection up to 51.1% (95%CI: 43.8-58.3%) and 57.3% (95%CI: 54.0-60.5%) against symptomatic infection within three months; however, this waned to 32.8% (95%CI: 16.8-48.7%) within six months. VE against severe Omicron infection following the primary course was 63.6% (95%CI: 57.5-69.7%) at three months, decreased to 49% (95%CI: 35.7-63.4%) within six months, and increased to 86% after the first or second booster dose.

Citing Articles

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.

Zhou G, Dael N, Verweij S, Balafas S, Mubarik S, Oude Rengerink K Eur Respir Rev. 2025; 34(175).

PMID: 39971395 PMC: 11836669. DOI: 10.1183/16000617.0222-2024.

Next generation sequencing of multiple SARS-CoV-2 infections in the Omicron Era.

Cavalli M, Campoli G, Anselmo A, Brandi R, Fortunato A, Di Spirito M Sci Rep. 2025; 15(1):3372.

PMID: 39870695 PMC: 11772649. DOI: 10.1038/s41598-024-84952-6.

Comprehensive statistical analysis reveals significant benefits of COVID-19 vaccination in hospitalized patients: propensity score, covariate adjustment, and feature importance by permutation.

de Moraes E, Pires M, Costa A, Nunes A, de Amorim C, Manenti E BMC Infect Dis. 2024; 24(1):1052.

PMID: 39333931 PMC: 11428431. DOI: 10.1186/s12879-024-09865-1.

The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.

Liao Y, Su J, Zhao J, Qin Z, Zhang Z, Gao W Front Immunol. 2024; 15:1359380.

PMID: 38881892 PMC: 11176464. DOI: 10.3389/fimmu.2024.1359380.

Vaccine Effectiveness against GP-Attended Symptomatic COVID-19 and Hybrid Immunity among Adults in Hungary during the 2022-2023 Respiratory Season Dominated by Different SARS-CoV-2 Omicron Subvariants.

Horvath J, Turi G, Krisztalovics K, Kristof K, Oroszi B Vaccines (Basel). 2024; 12(5).

PMID: 38793747 PMC: 11125656. DOI: 10.3390/vaccines12050496.

References

Zou Y, Huang D, Jiang Q, Guo Y, Chen C . The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. Front Public Health. 2022; 10:940956. PMC: 9326247. DOI: 10.3389/fpubh.2022.940956. View

Kirsebom F, Andrews N, Sachdeva R, Stowe J, Ramsay M, Lopez Bernal J . Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. Nat Commun. 2022; 13(1):7688. PMC: 9744366. DOI: 10.1038/s41467-022-35168-7. View

Collie S, Champion J, Moultrie H, Bekker L, Gray G . Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2021; 386(5):494-496. PMC: 8757569. DOI: 10.1056/NEJMc2119270. View

Araf Y, Akter F, Tang Y, Fatemi R, Parvez M, Zheng C . Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022; 94(5):1825-1832. PMC: 9015557. DOI: 10.1002/jmv.27588. View

Fowlkes A, Yoon S, Lutrick K, Gwynn L, Burns J, Grant L . Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(11):422-428. PMC: 8942308. DOI: 10.15585/mmwr.mm7111e1. View

Pulliam J, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome M . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022; 376(6593):eabn4947. PMC: 8995029. DOI: 10.1126/science.abn4947. View

Spensley K, Gleeson S, Martin P, Thomson T, Clarke C, Pickard G . Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. Kidney Int Rep. 2022; 7(6):1406-1409. PMC: 9006399. DOI: 10.1016/j.ekir.2022.04.005. View

Tartof S, Slezak J, Puzniak L, Hong V, Xie F, Ackerson B . Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 2022; 10(7):689-699. PMC: 9033225. DOI: 10.1016/S2213-2600(22)00101-1. View

Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N . Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis. PLoS Med. 2022; 19(12):e1004136. PMC: 9714718. DOI: 10.1371/journal.pmed.1004136. View

10.

Cao Y, Jian F, Xiao T, Song W, Yisimayi A, Huang W . Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022; 602(7898):657-663. PMC: 8866119. DOI: 10.1038/s41586-021-04385-3. View

11.

Kulper-Schiek W, Piechotta V, Pilic A, Batke M, Dreveton L, Geurts B . Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. Front Immunol. 2022; 13:940562. PMC: 9449804. DOI: 10.3389/fimmu.2022.940562. View

12.

Young-Xu Y, Zwain G, Izurieta H, Korves C, Powell E, Smith J . Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans. BMJ Open. 2022; 12(8):e063935. PMC: 9352567. DOI: 10.1136/bmjopen-2022-063935. View

13.

Grewal R, Kitchen S, Nguyen L, Buchan S, Wilson S, Costa A . Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. BMJ. 2022; 378:e071502. PMC: 9257064. DOI: 10.1136/bmj-2022-071502. View

14.

Gram M, Emborg H, Schelde A, Friis N, Nielsen K, Moustsen-Helms I . Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. PLoS Med. 2022; 19(9):e1003992. PMC: 9436060. DOI: 10.1371/journal.pmed.1003992. View

15.

Lauring A, Tenforde M, Chappell J, Gaglani M, Ginde A, McNeal T . Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMC: 8905308. DOI: 10.1136/bmj-2021-069761. View

16.

Buchan S, Nguyen L, Wilson S, Kitchen S, Kwong J . Vaccine Effectiveness of BNT162b2 Against Delta and Omicron Variants in Adolescents. Pediatrics. 2022; 150(3). DOI: 10.1542/peds.2022-057634. View

17.

Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M . Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August.... MMWR Morb Mortal Wkly Rep. 2022; 71(4):139-145. PMC: 9351525. DOI: 10.15585/mmwr.mm7104e3. View

18.

Tseng H, Ackerson B, Luo Y, Sy L, Talarico C, Tian Y . Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022; 28(5):1063-1071. PMC: 9117141. DOI: 10.1038/s41591-022-01753-y. View

19.

Suarez Castillo M, Khaoua H, Courtejoie N . Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. Euro Surveill. 2022; 27(16). PMC: 9027152. DOI: 10.2807/1560-7917.ES.2022.27.16.2200250. View

20.

Carazo S, Skowronski D, Brisson M, Barkati S, Sauvageau C, Brousseau N . Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. Lancet Infect Dis. 2022; 23(1):45-55. PMC: 9491856. DOI: 10.1016/S1473-3099(22)00578-3. View